Art. -Nr.: HY-134635

Dehydrozingerone

Kundenbewertung

Based on 1 Customer Validation

Dehydrozingerone is a ginger-derived component and cyclin D1 inhibitor that downregulates cyclin D1 expression and induces cell cycle G₁ phase arrest. Dehydrozingerone reduces the proliferative capacity of castration-resistant prostate cancer cells under in vitro conditions. Dehydrozingerone reduces subcutaneous tumor growth by inhibiting cell proliferation and angiogenesis. Dehydrozingerone exerts antibacterial and antifungal activities via its α,β-unsaturated carbonyl conjugated system. Dehydrozingerone can be used in studies related to castration-resistant prostate cancer, bacterial infections, and food spoilage fungal infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.98%
CAS. Nr.: 1080-12-2
Formel: C₁₁H₁₂O₃
Molecular Weight:192.21

Speicherung:

RT, stored under nitrogen.

In solvent -80°C, 1 year , -20°C, 6 months

Dehydrozingerone Chemical Structure

CAS. Nr.: 1080-12-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle HIV Isoform-spezifische Produkte anzeigen :

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	33.9 μM Compound: 4, DZ	Cytotoxicity against human 1A9 cells Cytotoxicity against human 1A9 cells	[PMID: 17591444]
A498	IC₅₀	125 μM Compound: DZG	Antiproliferative activity against human A498 cells after 72 hrs by MTT assay Antiproliferative activity against human A498 cells after 72 hrs by MTT assay	[PMID: 30429098]
A549	ED₅₀	>52 μM Compound: 4, DZ	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17591444]
A549	IC₅₀	>10 μg/mL Compound: 1	Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
BMDM	IC₅₀	7.5 μM Compound: 2g	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
DU-145	ED₅₀	>52 μM Compound: 4, DZ	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17591444]
HCT-116	IC₅₀	34.78 μM Compound: 1; DHZ; Dehydrozingerone	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108729]
HCT-116	IC₅₀	70 μM Compound: DZG	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-15	IC₅₀	65 μM Compound: DZG	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-8	ED₅₀	>52 μM Compound: 4, DZ	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 17591444]
HEK293	IC₅₀	64 μM Compound: DZG	Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 30429098]
K562	GI₅₀	85.33 μM Compound: 2	Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	GI₅₀	92 μM Compound: 2	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	IC₅₀	68 μM Compound: 4b'	In vitro cell growth inhibitory activity against K562 human chronic myelogenous leukemia cell line In vitro cell growth inhibitory activity against K562 human chronic myelogenous leukemia cell line	10.1016/S0960-894X(97)10147-0
KB	IC₅₀	>10 μg/mL Compound: 1	Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KB	IC₅₀	>10 μg/mL Compound: 1	Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
LNCaP	ED₅₀	51 μM Compound: 4, DZ	Cytotoxicity against human LN-Cap cells Cytotoxicity against human LN-Cap cells	[PMID: 17591444]
M14	IC₅₀	550 μM Compound: DZG	Antiproliferative activity against human M14 cells after 72 hrs by MTT assay Antiproliferative activity against human M14 cells after 72 hrs by MTT assay	[PMID: 30429098]
MCF7	IC₅₀	31 μM Compound: DZG	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30429098]
MCF7	IC₅₀	54.65 μM Compound: 1; DHZ; Dehydrozingerone	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30108729]
MDA-MB-231	IC₅₀	86 μM Compound: DZG	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30429098]
NCI-H322M	IC₅₀	96 μM Compound: DZG	Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay	[PMID: 30429098]
NCI-H460	GI₅₀	64.75 μM Compound: 2	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27908756]
OVCAR-4	IC₅₀	139 μM Compound: DZG	Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay	[PMID: 30429098]
PC-3	ED₅₀	>52 μM Compound: 4, DZ	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17591444]
PC-3	IC₅₀	43.21 μM Compound: 1; DHZ; Dehydrozingerone	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30108729]
PC-3	IC₅₀	68 μM Compound: DZG	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30429098]
Raji	IC₅₀	95 molar ratio Compound: DZG; Dehydrozingerone	Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA	[PMID: 26796952]
SNB-19	IC₅₀	138 μM Compound: DZG	Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay	[PMID: 30429098]
ZR-75-1	ED₅₀	>52 μM Compound: 4, DZ	Cytotoxicity against human ZR751 cells Cytotoxicity against human ZR751 cells	[PMID: 17591444]

In Vitro

Dehydrozingerone (0-200 μM; 48 h) inhibits the proliferation of rat castration-resistant prostate cancer PLS10 cells in vitro with an IC₅₀ of 153.13 μM^[1].
Dehydrozingerone (0-200 μM; 48 h) induces G1 phase cell cycle arrest and downregulates cyclin D1 expression in rat castration-resistant prostate cancer PLS10 cells at concentrations of 150 and 200 μM for 48 h^[1].
Dehydrozingerone (1 mg) exhibits strong antifungal activity against Aspergillus niger, Aspergillus ochraceus, Aspergillus flavus, and Penicillium sp., with the largest inhibition zones measured at 31.0 ± 1.0 mm and 31.5 ± 3.5 mm for Aspergillus niger and Penicillium sp., respectively^[2].
Dehydrozingerone (1041 μM; 5 to 7 d) exerts potent antifungal activity against multiple food spoilage fungal pathogens, with the largest inhibition zones observed against Penicillium chrysogenum (29.5 mm) and Aspergillus ochraceus (30.5 mm)^[3].
Dehydrozingerone (260-1041 μM; up to 10 d) inhibits growth and sporulation of Aspergillus ochraceus in a concentration- and time-dependent manner, with complete sporulation prevention at 781 μM when applied within 2 days of inoculation and 100% growth inhibition at 1041 μM after 5 d of incubation^[3].
Dehydrozingerone (260-1041 μM) reduces the levels of key biomolecules (DNA, RNA, protein, total sugars) and biomass in Aspergillus ochraceus, with the most pronounced effects on biomolecule levels observed at 260 μM and the highest growth inhibition at 1041 μM^[3].
Dehydrozingerone (520-1041 μM) disrupts the cellular morphology of Aspergillus ochraceus, causing hyphal collapse, conidial shrinkage, and mycelial damage, indicating interference with cell wall synthesis and fungal morphogenesis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

rat castration-resistant prostate cancer PLS10 cells
Concentration:

0, 25, 50, 100, 150, 200 μM
Incubation Time:

48 h
Result:

Significantly inhibited cell proliferation in a dose-dependent manner.
Reached an IC₅₀ value of 153.13 μM.

Cell Cycle Analysis^[1]

Cell Line:

rat castration-resistant prostate cancer PLS10 cells
Concentration:

0, 50, 100, 150, 200 μM
Incubation Time:

48 h
Result:

Increased the G1 phase cell population from 35.93% (control) to 42.88% and decreased the G2/M phase population from 48.18% (control) to 39.25% at 150 μM.
Increased the G1 phase cell population to 52.95% and decreased the G2/M phase population to 31.00% at 200 μM.
Significantly reduced cyclin D1 expression at 150 and 200 μM.

In Vivo

Dehydrozingerone (30 mg/kg; i.p.; twice weekly; 5 weeks) significantly inhibits prostate cancer xenograft growth (reducing final tumor volume to 24 cm³, p < 0.05) via suppression of tumor cell proliferation and angiogenesis, with no observed toxicity in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c-nu/nu (5-week-old male, subcutaneous xenograft model)^[1]
Dosage:

30 mg/kg
Administration:

i.p.; twice weekly; 5 weeks
Result:

Reduced final tumor volume from 96 cm³ (control) to 24 cm³.
Decreased Ki67-labeling index from 63 (control) to 59.
Increased percentage of TUNEL-positive apoptotic cells from 7% (control) to 10%.
Reduced percentage of CD31-positive vessel area significantly.

Chemical Information

CAS. Nr. 1080-12-2
Appearance Solid
Molecular Weight 192.21
Formel C₁₁H₁₂O₃
Color Off-white to light yellow
SMILES

CC(/C=C/C1=CC=C(O)C(OC)=C1)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

RT, stored under nitrogen

In solvent	-80°C	1 year
	-20°C	6 months

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (520.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.2026 mL

26.0132 mL

52.0264 mL

5 mM

1.0405 mL

5.2026 mL

10.4053 mL

10 mM

0.5203 mL

2.6013 mL

5.2026 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (26.01 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 5 mg/mL (26.01 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (26.01 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mapoung S, et al. Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo. Molecules. 2020;25(12):2737. Published 2020 Jun 12. [Content Brief]

[2]. Kubra IR, et al. Structure-function activity of dehydrozingerone and its derivatives as antioxidant and antimicrobial compounds. J Food Sci Technol. 2014;51(2):245-255. [Content Brief]

[3]. Kubra IR, et al. In vitro antifungal activity of dehydrozingerone and its fungitoxic properties. J Food Sci. 2013;78(1):M64-M69. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.2026 mL	26.0132 mL	52.0264 mL	130.0661 mL
	5 mM	1.0405 mL	5.2026 mL	10.4053 mL	26.0132 mL
	10 mM	0.5203 mL	2.6013 mL	5.2026 mL	13.0066 mL
	15 mM	0.3468 mL	1.7342 mL	3.4684 mL	8.6711 mL
	20 mM	0.2601 mL	1.3007 mL	2.6013 mL	6.5033 mL
	25 mM	0.2081 mL	1.0405 mL	2.0811 mL	5.2026 mL
	30 mM	0.1734 mL	0.8671 mL	1.7342 mL	4.3355 mL
	40 mM	0.1301 mL	0.6503 mL	1.3007 mL	3.2517 mL
	50 mM	0.1041 mL	0.5203 mL	1.0405 mL	2.6013 mL
	60 mM	0.0867 mL	0.4336 mL	0.8671 mL	2.1678 mL
	80 mM	0.0650 mL	0.3252 mL	0.6503 mL	1.6258 mL
	100 mM	0.0520 mL	0.2601 mL	0.5203 mL	1.3007 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dehydrozingerone

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Flavors and Fragrances Compound Library

High-Efficiency Gene Editing Compound Library

Alle HIV Isoform-spezifische Produkte anzeigen

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dehydrozingerone

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Flavors and Fragrances Compound Library

High-Efficiency Gene Editing Compound Library

Alle HIV Isoform-spezifische Produkte anzeigen

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dehydrozingerone Related Classifications

HY-134635 Related Classifications